Cardiovascular Risk in Children and Adolescents with Type 1 and Type 2 Diabetes Mellitus

Current Cardiovascular Risk Reports

Volumn 6, Issue 6, 2012, Pages 591-600

  Magge, Sheela N ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adipokines; Adiponectin; Body mass index; Cardiovascular risk; Carotid intimal medial thickness; Coronary artery calcification; Echocardiography; Flow mediated dilation of the brachial artery; Inflammation; Left ventricular mass; Lipids; Lipoprotein subclass particle analysis; Obesity; Pediatrics; Pulse wave analysis; Pulse wave velocity; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; FATTY ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIABETES CONTROL; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FOLLOW UP; HUMAN; HYPERGLYCEMIA; IMAGING; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; JUVENILE; KIDNEY DISEASE; MICROANGIOPATHY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PUBLIC HEALTH; RETINOPATHY; REVIEW; VASCULAR IMAGING; VITAMIN D DEFICIENCY;

EID: 84873863708     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-012-0274-9     Document Type: Review

References (139)

1. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med. 2006; 23(8): 857-66.
2. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith G, Bloch C, et al. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diabetes Care. 2007; 30(3): 503-9.
3. Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. Lancet. 2000; 355(9207): 873-6.
4. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM, et al. Prevalence of overweight and obesity in the United States, 1999-2004. Jama. 2006; 295(13): 1549-55.
5. Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996; 128(5 Pt 1): 591. Journal of Pediatrics. 1996; 128(5 Pt 1): 608-15.
6. Anonymous. Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care. 2000; 23(3): 381-9.
7. Liese AD, D'Agostino Jr RB, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, et al. The burden of diabetes mellitus among US youth: Prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006; 118(4): 1510-8.
8. American Academy of Pediatrics. National cholesterol education program: Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992; 89(3 Pt 2): 525-84.
9. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": An 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005; 28(12): 2901-7.
10. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman 3rd WP, Herderick EE, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the pathobiological determinants of atherosclerosis in youth study. Jama. 1999; 281(8): 727-35.
11. McGill Jr HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002; 105(23): 2712-8.
12. Berenson GS, Srinivasan SR, Bao W, Newman 3rd WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998; 338(23): 1650-6.
13. Freedman DS, Dietz WH, Tang R, Mensah GA, Bond MG, Urbina EM, et al. The relation of obesity throughout life to carotid intima-media thickness in adulthood: The Bogalusa Heart Study. Int J Obes Relat Metab Disord. 2004; 28(1): 159-66.
14. Mahoney LT, Burns TL, Stanford W, Thompson BH, Witt JD, Rost CA, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: The muscatine study. J Am Coll Cardiol. 1996; 27(2): 277-84.
15. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: The cardiovascular risk in young finns study. Jama. 2003; 290(17): 2277-83.
16. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987; 59(8): 750-5.
17. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977-86.
18. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643-53. PMCID: 2637991.
19. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003; 348(23): 2294-303. PMCID: 2701300.
20. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999; 84(5): 489-97.
21. Libby P, Plutzky J. Diabetic macrovascular disease: The glucose paradox? Circulation. 2002; 106(22): 2760-3.
22. Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, et al. Progression of coronary artery calcification in type 1 diabetes: The importance of glycemic control. Diabetes Care. 2003; 26(10): 2923-8.
23. Shamir R, Kassis H, Kaplan M, Naveh T, Shehadeh N. Glycemic control in adolescents with type 1 diabetes mellitus improves lipid serum levels and oxidative stress. Pediatr Diabetes. 2008; 9(2): 104-9.
24. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce Jr WM, Klein JB, et al. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab. 2004; 287(5): E896-905.
25. • Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes. 2011; 60(1): 306-14. PMCID: 3012187. This study used hyperinsulinemic euglycemic clamp studies to illustrate increased insulin resistance among Type 1 diabetes which predicted increased coronary artery calcification.
26. • Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010; 95(2): 513-21. PMCID: 2840859. This study investigated the effected of insulin resistance in children with type 1 diabetes.
27. Suys BE, Katier N, Rooman RP, Matthys D, Op De Beeck L, Du Caju MV, et al. Female children and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy. Diabetes Care. 2004; 27(8): 1947-53.
28. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991; 81(9): 1158-62. PMCID: 1405646.
29. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16(2): 434-44.
30. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37(12): 1595-607.
31. Boyd GS, Koenigsberg J, Falkner B, Gidding S, Hassink S. Effect of obesity and high blood pressure on plasma lipid levels in children and adolescents. Pediatrics. 2005; 116(2): 442-6.
32. Invitti C, Guzzaloni G, Gilardini L, Morabito F, Viberti G. Prevalence and concomitants of glucose intolerance in European obese children and adolescents. Diabetes Care. 2003; 26(1): 118-24.
33. Davis CL, Flickinger B, Moore D, Bassali R, Domel Baxter S, Yin Z, et al. Prevalence of cardiovascular risk factors in schoolchildren in a rural Georgia community. American Journal of the Medical Sciences. 2005; 330(2): 53-9.
34. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003; 163(11): 1306-16.
35. Leahy JL. Pathogenesis of Type 2 Diabetes Mellitus. Archives of Medical Research Current Trends in Diabetes. 2005; 36(3): 197-209.
36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837-53.
37. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577-89.
38. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Bmj. 2000; 321(7258): 405-12.
39. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J. 2006; 152(1): 27-38.
40. Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006; 29(6): 1300-6.
41. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25): 3143-421.
42. Kwiterovich Jr PO. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review. Am J Cardiol. 2000; 86(12A): 5L-10.
43. Petitti DB, Imperatore G, Palla SL, Daniels SR, Dolan LM, Kershnar AK, et al. Serum lipids and glucose control: The SEARCH for diabetes in youth study. Arch Pediatr Adolesc Med. 2007; 161(2): 159-65.
44. •• Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics. 2011; 128 Suppl 5: S213-56. These guidelines by the NHLBI recommend more aggressive lipid cut-offs for children, and recognize both type 1 and type 2 diabetes as conditions associated with accelerated atherosclerosis.
45. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, et al. Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American heart association expert panel on population and prevention science; The councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the interdisciplinary working group on quality of care and outcomes research: Endorsed by the american academy of pediatrics. Circulation. 2006; 114(24): 2710-38.
46. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340(2): 115-26.
47. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation. 2003; 107(3): 499-511.
48. Miller J, Rosenbloom A, Silverstein J. Childhood obesity. J Clin Endocrinol Metab. 2004; 89(9): 4211-8.
49. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation. 2004; 110(7): 803-9.
50. National Cholesterol Education Program (NCEP). Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992; 89(3): 495-501.
51. Rodriguez BL, Fujimoto WY, Mayer-Davis EJ, Imperatore G, Williams DE, Bell RA, et al. Prevalence of cardiovascular disease risk factors in U. S. children and adolescents with diabetes: The SEARCH for diabetes in youth study. Diabetes Care. 2006; 29(8): 1891-6.
52. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003; 157(8): 821-7.
53. Standards of medical care in diabetes-2011. Diabetes Care. 2011; 34 Suppl 1: S11-61. PMCID: 3006050.
54. Reh CM, Mittelman SD, Wee CP, Shah AC, Kaufman FR, Wood JR. A longitudinal assessment of lipids in youth with type 1 diabetes. Pediatr Diabetes. 2011; 12(4 Pt 2): 365-71.
55. Frontini MG, Srinivasan SR, Xu JH, Tang R, Bond MG, Berenson G. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). Am J Cardiol. 2007; 100(1): 64-8.
56. Rainwater DL, McMahan CA, Malcom GT, Scheer WD, Roheim PS, McGill Jr HC, et al. Lipid and apolipoprotein predictors of atherosclerosis in youth: Apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. Arterioscler Thromb Vasc Biol. 1999; 19(3): 753-61.
57. • Li C, Ford ES, McBride PE, Kwiterovich PO, McCrindle BW, Gidding SS. Non-high-density lipoprotein cholesterol concentration is associated with the metabolic syndrome among US youth aged 12-19 years. J Pediatr. 2011; 158(2): 201-7. This paper establishes non-HDL cut-offs for youth at increased risk for metabolic syndrome.
58. • Dalla Pozza R, Beyerlein A, Thilmany C, Weissenbacher C, Netz H, Schmidt H, et al. The effect of cardiovascular risk factors on the longitudinal evolution of the carotid intima medial thickness in children with type 1 diabetes mellitus. Cardiovasc Diabetol. 2011; 10: 53. PMCID: 3148557. One of the first longitudinal studies of progression of CIMT over time in youth with diabetes.
59. Shah AS, Dolan LM, Kimball TR, Gao Z, Khoury PR, Daniels SR, et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009; 94(10): 3740-5. PMCID: 2758732.
60. • Wadwa RP, Urbina EM, Anderson AM, Hamman RF, Dolan LM, Rodriguez BL, et al. Measures of arterial stiffness in youth with type 1 and type 2 diabetes: The SEARCH for diabetes in youth study. Diabetes Care. 2010; 33(4): 881-6. PMCID: 2845046. This manuscript compares arterial stiffness in youth with type 1 and type 2 diabetes.
61. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003; 52(2): 453-62.
62. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990; 82(2): 495-506.
63. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 1998; 18(7): 1046-53.
64. Perez-Mendez O, Torres-Tamayo M, Posadas-Romero C, Vidaure Garces V, Carreon-Torres E, Mendoza-Perez E, et al. Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. Clin Chim Acta. 2007; 376(1-2): 17-22.
65. Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS. Levels and correlates of LDL and VLDL particle sizes among children: The Bogalusa heart study. Atherosclerosis. 2000; 152(2): 441-9.
66. • Burns SF, Lee SJ, Arslanian SA. Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth. J Pediatr. 2012. This paper identifies calculated indices predictive of increased small dense LDL, using a standard lipid panel. These indices may be useful in clinic al practice to identify children with increased CVD risk.
67. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12): 836-43.
68. Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102(1): 42-7.
69. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes. 2004; 112(7): 378-82.
70. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004; 350(23): 2362-74.
71. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001; 286(3): 327-34.
72. Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med. 2004; 21(8): 810-7.
73. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003; 11(4): 525-31.
74. Dzienis-Straczkowska S, Straczkowski M, Szelachowska M, Stepien A, Kowalska I, Kinalska I. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care. 2003; 26(3): 875-80.
75. Gupta A, Ten S, Anhalt H. Serum levels of soluble tumor necrosis factor-alpha receptor 2 are linked to insulin resistance and glucose intolerance in children. J Pediatr Endocrinol Metab. 2005; 18(1): 75-82.
76. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. Jama. 2004; 291(16): 1978-86.
77. Miller J, Silverstein J. Cardiovascular risk factors in childhood diabetes. The Endocrinologist. 2003; 13(5): 394-407.
78. Desideri G, De Simone M, Iughetti L, Rosato T, Iezzi ML, Marinucci MC, et al. Early activation of vascular endothelial cells and platelets in obese children. Journal of Clinical Endocrinology & Metabolism. 2005; 90(6): 3145-52.
79. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005; 3(8): 1879-83.
80. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: Implication of vascular disease. J Surg Res. 2005; 126(1): 121-9.
81. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004; 89(6): 2563-8.
82. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: From obesity to cardiovascular disease. Obes Rev. 2009; 10(3): 269-79.
83. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361(9353): 226-8.
84. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100(25): 2473-6.
85. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20(6): 1595-9.
86. Weiss R, Taksali SE, Dufour S, Yeckel CW, Papademetris X, Cline G, et al. The "obese insulin-sensitive" adolescent: Importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab. 2005; 90(6): 3731-7.
87. Morales A, Wasserfall C, Brusko T, Carter C, Schatz D, Silverstein J, et al. Adiponectin and leptin concentrations may aid in discriminating disease forms in children and adolescents with type 1 and type 2 diabetes. Diabetes Care. 2004; 27(8): 2010-4.
88. Magge SN, Stettler N, Koren D, Levitt Katz LE, Gallagher PR, Mohler 3rd ER, et al. Adiponectin Is Associated with Favorable Lipoprotein Profile, Independent of BMI and Insulin Resistance, in Adolescents. J Clin Endocrinol Metab. 2011; 96(5): 1549-54. PMCID: 3085202.
89. Beauloye V, Zech F, Tran HT, Clapuyt P, Maes M, Brichard SM. Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab. 2007; 92(8): 3025-32.
90. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372(6505): 425-32.
91. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006; 189(1): 47-60.
92. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5): 292-5.
93. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001; 104(25): 3052-6.
94. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord. 2001; 25(6): 805-10.
95. Targher G, Bertolini L, Padovani R, Zenari L, Scala L, Cigolini M, et al. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf). 2006; 65(5): 593-7.
96. Diaz VA, Mainous 3rd AG, Carek PJ, Wessell AM, Everett CJ. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: Implications for health disparities. J Am Board Fam Med. 2009; 22(5): 521-7.
97. Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care. 2011; 34(6): 1400-2. PMCID: 3114351.
98. •• Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension. 2009; 54(5): 919-50. Scientific statement by the AHA describing the methodology for non-invasive vascular imaging techniques to assess CVD risk, and identifying gaps in the scientific evidence warranting further research.
99. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The rotterdam study. Circulation. 1997; 96(5): 1432-7.
100. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997; 146(6): 483-94.
101. Leinonen ES, Hiukka A, Hurt-Camejo E, Wiklund O, Sarna SS. Mattson Hulten L, et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. Journal of Internal Medicine. 2004; 256(2): 119-27.
102. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004; 110(2): 214-9.
103. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: Results from a controlled randomized study. Circulation. 2005; 111(19): 2525-31.
104. Meyer AA, Kundt G, Steiner M, Schuff-Werner P, Kienast W. Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: The impact of cardiovascular risk factors. Pediatrics. 2006; 117(5): 1560-7.
105. Zhu W, Li M, Huang X, Neubauer H. Association of hyperviscosity and subclinical atherosclerosis in obese schoolchildren. European Journal of Pediatrics. 2005; 164(10): 639-45.
106. Stabouli S, Kotsis V, Papamichael C, Constantopoulos A, Zakopoulos N. Adolescent obesity is associated with high ambulatory blood pressure and increased carotid intimal-medial thickness. The Journal of Pediatrics. 2005; 147(5): 651-6.
107. Jarvisalo MJ, Putto-Laurila A, Jartti L, Lehtimaki T, Solakivi T, Ronnemaa T, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes. 2002; 51(2): 493-8.
108. Peppa-Patrikiou M, Scordili M, Antoniou A, Giannaki M, Dracopoulou M, Dacou-Voutetakis C. Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors. Diabetes Care. 1998; 21(6): 1004-7.
109. Krantz JS, Mack WJ, Hodis HN, Liu CR, Liu CH, Kaufman FR, et al. Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. Journal of Pediatrics. 2004; 145(4): 452-7.
110. Singh TP, Groehn H, Kazmers A. Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 2003; 41(4): 661-5.
111. Parikh A, Sochett EB, McCrindle BW, Dipchand A, Daneman A, Daneman D. Carotid artery distensibility and cardiac function in adolescents with type 1 diabetes. J Pediatr. 2000; 137(4): 465-9.
112. Babar GS, Zidan H, Widlansky ME, Das E, Hoffmann RG, Daoud M, et al. Impaired endothelial function in preadolescent children with type 1 diabetes. Diabetes Care. 2011; 34(3): 681-5. PMCID: 3041207.
113. Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, Dahl-Jorgensen K. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care. 2010; 33(9): 2043-8. PMCID: 2928360.
114. Krebs A, Schmidt-Trucksass A, Doerfer J, Grulich-Henn J, Holder M, Hecker W, et al. Cardiovascular risk in pediatric type 1 diabetes: Sex-specific intima-media thickening verified by automatic contour identification and analyzing systems. Pediatr Diabetes. 2012; 13(3): 251-8.
115. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340(8828): 1111-5.
116. Jarvisalo MJ, Ronnemaa T, Volanen I, Kaitosaari T, Kallio K, Hartiala JJ, et al. Brachial artery dilatation responses in healthy children and adolescents. Am J Physiol Heart Circ Physiol. 2002; 282(1): H87-92.
117. Faulx MD, Wright AT, Hoit BD. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J. 2003; 145(6): 943-51.
118. Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, Sidi D, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: A prospective study. Lancet. 2001; 358(9291): 1400-4.
119. Watts K, Beye P, Siafarikas A, Davis EA, Jones TW, O'Driscoll G, et al. Exercise training normalizes vascular dysfunction and improves central adiposity in obese adolescents. J Am Coll Cardiol. 2004; 43(10): 1823-7.
120. Jarvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, Laine S, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation. 2004; 109(14): 1750-5.
121. Battelino N, Sebestjen M, Keber I, Blagus R, Hovnik T, Bratina N, et al. Endothelial nitric oxide synthase T(-786)C polymorphism in children and adolescents with type 1 diabetes and impaired endothelium-dependent dilatation. Horm Res Paediatr. 2011; 76(4): 248-53.
122. Aggoun Y, Szezepanski I, Bonnet D. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events in children. Pediatr Res. 2005; 58(2): 173-8.
123. Wildman RP, Mackey RH, Bostom A, Thompson T, Sutton-Tyrrell K. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension. 2003; 42(4): 468-73.
124. Gungor N, Thompson T, Sutton-Tyrrell K, Janosky J, Arslanian S, Full N, et al. Early signs of cardiovascular disease in youth with obesity and type 2 diabetes. Diabetes Care. 2005; 28(5): 1219-21.
125. Urbina EM, Wadwa RP, Davis C, Snively BM, Dolan LM, Daniels SR, et al. Prevalence of increased arterial stiffness in children with type 1 diabetes mellitus differs by measurement site and sex: The SEARCH for diabetes in youth study. J Pediatr. 2010; 156(5): 731-7. 7 e1.
126. Collins RT, Somes GW, Alpert BS. Differences in arterial compliance among normotensive adolescent groups: Collins arterial compliance in adolescents. Pediatr Cardiol. 2008; 29(5): 929-34.
127. Reusz GS, Cseprekal O, Temmar M, Kis E, Cherif AB, Thaleb A, et al. Reference values of pulse wave velocity in healthy children and teenagers. Hypertension. 2010; 56(2): 217-24.
128. Shah AS, Dolan LM, Gao Z, Kimball TR, Urbina EM. Racial differences in arterial stiffness among adolescents and young adults with type 2 diabetes. Pediatr Diabetes. 2012; 13(2): 170-5. PMCID: 3210878.
129. Gunczler P, Lanes R, Soros A, Verdu L, Ramon Y, Guevara B, et al. Coronary artery calcification, serum lipids, lipoproteins, and peripheral inflammatory markers in adolescents and young adults with type 1 diabetes. J Pediatr. 2006; 149(3): 320-3.
130. Starkman HS, Cable G, Hala V, Hecht H, Donnelly CM. Delineation of prevalence and risk factors for early coronary artery disease by electron beam computed tomography in young adults with type 1 diabetes. Diabetes Care. 2003; 26(2): 433-6.
131. Chinali M, de Simone G, Roman MJ, Lee ET, Best LG, Howard BV, et al. Impact of obesity on cardiac geometry and function in a population of adolescents: The strong heart study. J Am Coll Cardiol. 2006; 47(11): 2267-73.
132. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322(22): 1561-6.
133. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991; 114(5): 345-52.
134. Li X, Li S, Ulusoy E, Chen W, Srinivasan SR, Berenson GS. Childhood adiposity as a predictor of cardiac mass in adulthood: The bogalusa heart study. Circulation. 2004; 110(22): 3488-92.
135. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation. 1995; 91(9): 2400-6.
136. Crowley DI, Khoury PR, Urbina EM, Ippisch HM, Kimball TR. Cardiovascular impact of the pediatric obesity epidemic: Higher left ventricular mass is related to higher body mass index. J Pediatr. 2011; 158(5): 709-14.
137. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr. 2009; 22(6): 709-14.
138. Benitez-Aguirre P, Craig ME, Sasongko MB, Jenkins AJ, Wong TY, Wang JJ, et al. Retinal vascular geometry predicts incident retinopathy in young people with type 1 diabetes: A prospective cohort study from adolescence. Diabetes Care. 2011; 34(7): 1622-7. PMCID: 3120178.
139. Benitez-Aguirre PZ, Sasongko MB, Craig ME, Jenkins AJ, Cusumano J, Cheung N, et al. Retinal vascular geometry predicts incident renal dysfunction in young people with type 1 diabetes. Diabetes Care. 2012; 35(3): 599-604. PMCID: 3322713.